IN2014MU01042A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU01042A IN2014MU01042A IN1042MU2014A IN2014MU01042A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A IN 1042MU2014 A IN1042MU2014 A IN 1042MU2014A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A
- Authority
- IN
- India
- Prior art keywords
- compositions
- component
- relates
- dabigatran
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (hu) | 2014-03-26 | 2015-03-26 | |
| PCT/IN2015/000142 WO2015145462A1 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical compositions of dabigatran |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (hu) | 2014-03-26 | 2015-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU01042A true IN2014MU01042A (hu) | 2015-10-02 |
Family
ID=54194086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1042MU2014 IN2014MU01042A (hu) | 2014-03-26 | 2015-03-26 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2014MU01042A (hu) |
| WO (1) | WO2015145462A1 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
| WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
| TR201617984A2 (tr) * | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin farmasöti̇k kompozi̇syonlari |
| WO2019004980A2 (en) | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |
| TR201706848A2 (tr) | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| TR201722323A2 (tr) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
| TR201722630A2 (hu) * | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
| TR201905308A2 (tr) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of dabigatran etexilate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| JP3716901B2 (ja) | 1999-04-14 | 2005-11-16 | シオノギクオリカプス株式会社 | セルロースエーテルフィルム |
| EP1485094B2 (de) | 2002-03-07 | 2020-03-25 | Boehringer Ingelheim International GmbH | Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze |
| DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| WO2011107427A1 (en) | 2010-03-01 | 2011-09-09 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
| JP2015504903A (ja) | 2012-01-24 | 2015-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の経口投与用ダビガトラン製剤 |
| HRP20211606T1 (hr) | 2012-02-21 | 2022-01-21 | Towa Pharmaceutical Europe, S.L. | Oralni farmaceutski pripravci dabigatran-eteksilata |
-
2015
- 2015-03-26 WO PCT/IN2015/000142 patent/WO2015145462A1/en active Application Filing
- 2015-03-26 IN IN1042MU2014 patent/IN2014MU01042A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015145462A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MU01042A (hu) | ||
| IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
| EP3206706A4 (en) | Stable injectable composition of pharmaceutically active agents and process for its preparation | |
| EP3295952A4 (en) | Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| ZA201605379B (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| IL260766B (en) | Continuous production of complexes containing active pharmaceutical ingredients | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| EP3347022A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING DUTASTERIDE AND FORMULATION IN CAPSULE COMPRISING SAME | |
| EP3311817A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| EP3530654A4 (en) | CARBOXYLIC ACID COMPOUND WITH QUINOLINYL SUBSTITUTE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| EP3167893A4 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
| EP3425388A4 (en) | METHOD OF EVALUATING PAIN CAUSED BY ADMINISTRATION OF DRUG SOLUTION, METHOD OF SELECTING DRUG SOLUTION DELIVERY | |
| EP3219311A4 (en) | Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof | |
| ZA201901004B (en) | High drug loaded tablet composition for treating hiv | |
| IL257689A (en) | Pharmacological preparations and methods for the treatment of diseases associated with hypoxia | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases | |
| SG10201810362SA (en) | Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition |